Literature DB >> 8785455

Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine.

M Adachi1, R Takayanagi, T Yanase, Y Sakai, S Ikuyama, H Nakagaki, Y Osamura, N Sanno, H Nawata.   

Abstract

A 56-year-old male patient with cyclic Cushing's disease remained in a state of remission for more than one year with a relatively low dose of bromocriptine (2.5-3.75 mg/day). It has been reported that bromocriptine treatment for cyclic Cushing's disease induces only a transient remission; in the most effective cases, a relatively high dose (40 mg/day) was necessary. In the hypercortisolemic state, plasma adrenocorticotropic hormone (ACTH) and serum cortisol were not suppressed by dexamethasone and did not respond to corticotropin-releasing factor (CRF). An antehypophysectomy was not effective, even though the resected tissue contained ACTH-positive microadenomas. The present observations thus indicate the effectiveness of bromocriptine for some patients with this rare disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8785455     DOI: 10.2169/internalmedicine.35.207

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Cyclic Cushing's disease with paradoxical response to dexamethasone.

Authors:  S Checchi; L Brilli; E Guarino; C Ciuoli; G Di Cairano; P Mazzucato; F Pacini
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

3.  Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline.

Authors:  G T'Sjoen; I Defeyter; J Van De Saffele; R Rubens; M Vandeweghe
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.